Masitinib: Difference between revisions
Rabin Bista (talk | contribs) Created page with "{{Drugbox | drug_name = | IUPAC_name = 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide | image..." |
m Protected "Masitinib": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
(No difference)
| |
Latest revision as of 16:39, 20 August 2015
{{Drugbox | drug_name = | IUPAC_name = 4-[(4-Methylpiperazin-1-yl)methyl]-N-(4-methyl-3-{[4-(pyridin-3-yl)-1,3-thiazol-2-yl]amino}phenyl)benzamide | image = Masitinib Wiki str.png
| alt = | caption =
| tradename = Masivet, Kinavet | Drugs.com = International Drug Names | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration =
| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =
| CAS_number = 790299-79-5 | ATCvet = | ATC_prefix = L01 | ATC_suffix = XE22 | ATC_supplemental = | PubChem = 10074640 | ChEMBL = 1908391 | ChemSpiderID = 8250179 | DrugBank =
| C=28 | H=30 | N=6 | O=1 | S=1 | molecular_weight = 498.64 g/mol | smiles = O=C(c1ccc(cc1)CN2CCN(C)CC2)Nc3cc(c(cc3)C)Nc4nc(cs4)c5cccnc5 | StdInChI = InChI=1S/C28H30N6OSc1-20-5-10-24(16-25(20)31-28-32-26(19-36-28)23-4-3-11-29-17-23)30-27(35)22-8-6-21(7-9-22)18-34-14-12-33(2)13-15-34h3-11,16-17,19H,12-15,18H2,1-2H3,(H,30,35)(H,31,32) | StdInChIKey = WJEOLQLKVOPQFV-UHFFFAOYSA-N }}
|
WikiDoc Resources for Masitinib |
|
Articles |
|---|
|
Most recent articles on Masitinib |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Masitinib at Clinical Trials.gov Clinical Trials on Masitinib at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Masitinib
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Masitinib Discussion groups on Masitinib Directions to Hospitals Treating Masitinib Risk calculators and risk factors for Masitinib
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Masitinib |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Masitinib is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs.[1][2] Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.
Masitinib is being studied for several human conditions including cancers. It is used in Europe to fight orphan diseases.[3]
Mechanism of action
Masitinib inhibits the receptor tyrosine kinase c-Kit which is displayed by various types of tumour.[2] It also inhibits the platelet derived growth factor receptor (PDGFR) and fibroblast growth factor receptor (FGFR).[citation needed]
References
- ↑ Hahn, K.A.; Oglivie, G.; Rusk, T.; Devauchelle, P.; Leblanc, A.; Legendre, A.; Powers, B.; Leventhal, P.S.; Kinet, J.-P.; Palmerini, F.; Dubreuil, P.; Moussy, A.; Hermine, O. (2008). "Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors". Journal of Veterinary Internal Medicine. 22 (6): 1301–1309. doi:10.1111/j.1939-1676.2008.0190.x. ISSN 0891-6640.
- ↑ 2.0 2.1 Information about Masivet at the European pharmacy agency website
- ↑ Orphan designation for Masitinib at the European pharmacy agency website